Anthera Pharmaceuticals, Inc. (ANTH)

[Paulieme]

Rhenman & Partners Asset Management Has $1,160,000 Position in Anthera Pharmaceuticals Inc (ANTH)
Posted by Logan Wallace on Feb 25th, 2016--- Rhenman & Partners Asset Management maintained its stake in Anthera Pharmaceuticals Inc (NASDAQ:ANTH) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 250,000 shares of the biopharmaceutical company’s stock at the end of the fourth quarter. Rhenman & Partners Asset Management owned about 0.63% of Anthera Pharmaceuticals worth $1,160,000 at the end of the most recent quarter.
Anthera Pharmaceuticals Inc (NASDAQ:ANTH) traded down 2.34% during mid-day trading on Thursday, hitting $2.92. The company had a trading volume of 335,731 shares. The firm’s market capitalization is $116.44 million. Anthera Pharmaceuticals Inc has a 12 month low of $2.28 and a 12 month high of $11.65. The company has a 50-day moving average price of $3.12 and a 200 day moving average price of $5.59.
ANTH has been the subject of a number of analyst reports. Zacks Investment Research upgraded Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 price target for the company in a research report on Monday, January 11th. Jefferies Group restated a “buy” rating and issued a $9.00 price target (down previously from $12.00) on shares of Anthera Pharmaceuticals in a research report on Friday, February 19th. Finally, Citigroup Inc. reduced their price target on Anthera Pharmaceuticals from $15.00 to $11.00 in a research report on Friday, February 19th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $10.45.--- http://www.tickerreport.com/banking-finance/1432922/rhenman-partners-asset-management-has-1160000-position-in-anthera-pharmaceuticals-inc-anth/